Alerus Financial NA Sells 6,004 Shares of Stryker Co. (NYSE:SYK)

Alerus Financial NA reduced its position in shares of Stryker Co. (NYSE:SYKGet Rating) by 34.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,604 shares of the medical technology company’s stock after selling 6,004 shares during the quarter. Alerus Financial NA’s holdings in Stryker were worth $3,103,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Retirement Group LLC raised its stake in Stryker by 86.8% during the 4th quarter. Retirement Group LLC now owns 99 shares of the medical technology company’s stock worth $27,000 after buying an additional 46 shares during the period. Cassady Schiller Wealth Management LLC purchased a new stake in shares of Stryker in the fourth quarter worth approximately $27,000. Disciplined Investments LLC purchased a new stake in shares of Stryker in the fourth quarter worth approximately $28,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Stryker in the fourth quarter worth approximately $31,000. Finally, Bell Investment Advisors Inc purchased a new stake in shares of Stryker in the third quarter worth approximately $37,000. 74.52% of the stock is currently owned by institutional investors and hedge funds.

NYSE:SYK traded up $1.20 during trading hours on Wednesday, hitting $234.48. 12,560 shares of the company’s stock traded hands, compared to its average volume of 1,516,914. The firm has a market cap of $88.67 billion, a P/E ratio of 44.35, a P/E/G ratio of 2.61 and a beta of 0.99. Stryker Co. has a 52 week low of $224.02 and a 52 week high of $281.16. The business’s fifty day simple moving average is $253.41 and its two-hundred day simple moving average is $256.40. The company has a quick ratio of 1.18, a current ratio of 1.98 and a debt-to-equity ratio of 0.92.

Stryker (NYSE:SYKGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The medical technology company reported $1.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.93 by $0.04. The company had revenue of $4.30 billion during the quarter, compared to analyst estimates of $4.19 billion. Stryker had a return on equity of 24.09% and a net margin of 11.56%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $1.93 earnings per share. On average, analysts expect that Stryker Co. will post 9.64 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Thursday, June 30th will be given a dividend of $0.695 per share. The ex-dividend date is Wednesday, June 29th. This represents a $2.78 dividend on an annualized basis and a yield of 1.19%. Stryker’s payout ratio is 52.85%.

A number of brokerages recently commented on SYK. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Monday, May 2nd. Morgan Stanley decreased their price target on Stryker from $305.00 to $275.00 and set an “equal weight” rating for the company in a research report on Monday, January 31st. Evercore ISI reaffirmed an “outperform” rating and set a $284.00 price target on shares of Stryker in a research report on Tuesday, March 15th. TheStreet downgraded Stryker from a “b” rating to a “c+” rating in a research report on Monday, May 2nd. Finally, Piper Sandler decreased their price target on Stryker from $315.00 to $290.00 in a research report on Friday, April 29th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $291.53.

About Stryker (Get Rating)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.

Recommended Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKGet Rating).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.